Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCFA ADMINISTRATOR NOMINEE VLADECK BRINGS ADMINISTRATIVE AND POLICY BACKGROUND

Executive Summary

HCFA ADMINISTRATOR NOMINEE VLADECK BRINGS ADMINISTRATIVE AND POLICY BACKGROUND to the top position at the Health Care Financing Administration at a time when both Congress and President Clinton are focused on cutting health care costs. The White House announced Bruce Vladeck's nomination for the position of HCFA administrator on March 5. Vladeck, 43, has been president of the United Hospital Fund of New York since 1983, directing the fund's involvement in grant-making, health services research and policy development. Vladeck is also a director of the New York City Health and Hospitals Corporation. Additionally, he serves as co-chair of the New York State Council on Health Care Financing. At the national level, Vladeck has served on the federal Medicare Prospective Payment Assessment Commission since 1986, chairing ProPAC's Subcommittee on Hospital Inpatient Services. He was acting ProPAC chairman during the Clinton transition period, while Stuart Altman headed a health care policy development group for the incoming administration. Before joining the United Hospital Fund of New York, Vladeck was assistant VP of the Robert Wood Johnson Foundation. From 1979 until 1982, he was assistant commissioner for health planning and resources development of the New Jersey State Department of Health. A good portion of his experience is in regulatory-oriented programs. For example, Vladeck directed New Jersey's State Health Planning and Development Agency, where he oversaw the implementation of the state's all-payer, DRG-based hospital prospective payment system. Vladeck received a BA in government from Harvard and an MA and PhD in political science from the University of Michigan. From 1974 to 1979, he was an assistant and associate professor of public health and political science at Columbia University. Among his many advisory affiliations, Vladeck is a member of New York State's AIDS Advisory Council and the Governor's Health Care Advisory Board. He published a book entitled Unloving Care: The Nursing Home Tragedy. Among the policy options put forward by the Clinton Administration and Congress for reducing the national deficit, many target Medicare and Medicaid spending. Clinton's economic plan, unveiled Feb. 17, includes proposals to repeal the prohibition against restrictive state Medicaid formularies and to reduce Medicare reimbursement to dialysis centers for Amgen's Epogen ("The Pink Sheet" Feb. 22, p. 8).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel